{
  "abstract": "This study aims to investigate the efficacy and influencing factors of rituximab (RTX) in the treatment of idiopathic membranous nephropathy (IMN). A total of 46 patients with IMN visited and followed up regularly in our hospital were included in this study. The patients were divided into 2 groups, with 23 patients receiving RTX treatment (RTX group) and 23 patients receiving treatment with cyclophosphamide (CTX group). The clinical data of the patients, including urine examination, blood test, efficacy evaluation results, and adverse events (AEs) were analyzed retrospectively. The changes in clinical and biochemical indicators were compared in RTX groups before and after treatment, and the clinical efficacy and influencing factors of RTX treatment for IMN were evaluated. After 6 months of treatment, in the RTX group, compared to baseline, there was a significant decrease in 24-hour urine protein, total cholesterol, and B lymphocyte count (P < .001, P = .010, P < .001), while albumin (ALB), globulin, and natural killer cells showed a significant increase compared to baseline (P < .001, P < .001, P < .001). After 6 months of treatment, the RTX group showed significantly higher glomerular filtration rate, higher levels of ALB, and higher levels of globulin compared to the CTX group, with statistical significance (P = .042, P = .003, P < .001). Among patients with positive anti-PLA2R antibodies at baseline, the antibody clearance rate at 6 months was significantly higher in the RTX group than in the CTX group (P = .035). By the end of follow-up, the overall remission rates were 91.3% for the RTX group and 87.0% for the CTX group, with no statistically significant difference between the 2 groups (P > .99). A univariate analysis of the correlation between clinical characteristics, laboratory tests, and the efficacy of RTX treatment found that lower baseline 24-hour urine protein levels appeared to be associated with a higher likelihood of achieving remission (P = .035). AEs were observed in 17.4% of RTX-treated patients versus 52.2% of CTX-treated patients (P = .030). RTX appeared to be effective in patients with IMN and was associated with a more favorable safety profile compared with CTX.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Nephrology, The First People’s Hospital of Xiaoshan District, Hangzhou, Zhejiang Province, China",
    "Medical Device Inspection Section, Zhejiang Center for Drug Inspection, Hangzhou, Zhejiang Province, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiaofei Xu",
      "orcid": "0000-0003-1385-4948"
    },
    {
      "affs": [
        1
      ],
      "name": "Qiwei Zhou"
    },
    {
      "affs": [
        0
      ],
      "name": "Subo Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiaoru Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiaoyun Zhang",
      "orcid": "0009-0006-8501-017X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5zfy37pnn6m7s.bib",
  "cited_by": 0,
  "doi": "10.1097/md.0000000000051442",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727179/?tool=EBI",
  "id": "5zfy37pnn6m7s",
  "issns": [
    "0304-5412",
    "1536-5964",
    "0025-7974"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13727179",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "5200"
    ],
    [
      "heading",
      "Observational Study"
    ],
    [
      "heading",
      "Research Article"
    ]
  ],
  "openalex": null,
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727179/pdf/?tool=EBI",
  "pmcid": "PMC13727179",
  "pmid": null,
  "published": "2026-10-30",
  "publisher": "Wolters Kluwer Health",
  "ris": "https://research.draconitic.com/paper/5zfy37pnn6m7s.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T15:20:51Z",
      "native_id": "PMC:PMC13727179",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13727179"
    },
    {
      "first_seen": "2026-11-05T12:23:18Z",
      "native_id": "PMC13727179",
      "source": "pmc",
      "url": "https://doi.org/10.1097/md.0000000000051442"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Efficacy and influencing factors of rituximab in idiopathic membranous nephropathy : A real-world retrospective study",
  "title_text": "Efficacy and influencing factors of rituximab in idiopathic membranous nephropathy : A real-world retrospective study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:22:54Z",
  "url": "https://research.draconitic.com/paper/5zfy37pnn6m7s",
  "venue": "Medicine",
  "versions": []
}